Business · 12/12/2019Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for BRIVIACT INJECTION New Drug Application
Summary
The US Food and Drug Administration has officially confirmed the regulatory review period for BRIVIACT INJECTION, a new drug application submitted to the US Patent and Trademark Office, in accordance with federal regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →